CINECA IRIS Institutional Research Information System

SANGIOLO, Dario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.474
AS - Asia 4.739
EU - Europa 4.719
SA - Sud America 579
AF - Africa 122
OC - Oceania 48
Continente sconosciuto - Info sul continente non disponibili 10
Totale 18.691
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.934
IT - Italia 1.691
SG - Singapore 1.552
CN - Cina 1.454
DE - Germania 749
VN - Vietnam 472
CA - Canada 439
BR - Brasile 437
GB - Regno Unito 414
IE - Irlanda 307
FI - Finlandia 292
FR - Francia 278
SE - Svezia 268
TR - Turchia 219
KR - Corea 170
JP - Giappone 161
HK - Hong Kong 150
IN - India 150
PL - Polonia 120
UA - Ucraina 100
NL - Olanda 97
ES - Italia 89
BD - Bangladesh 84
ID - Indonesia 73
AR - Argentina 63
MX - Messico 57
TW - Taiwan 57
AT - Austria 47
RU - Federazione Russa 45
AU - Australia 42
BE - Belgio 37
ZA - Sudafrica 34
CH - Svizzera 33
NO - Norvegia 33
IQ - Iraq 29
PT - Portogallo 27
TH - Thailandia 27
EC - Ecuador 21
JM - Giamaica 19
SA - Arabia Saudita 18
VE - Venezuela 18
IL - Israele 16
IR - Iran 16
SN - Senegal 16
CO - Colombia 15
GR - Grecia 14
RO - Romania 14
PK - Pakistan 13
UZ - Uzbekistan 12
DZ - Algeria 11
EG - Egitto 11
HR - Croazia 11
JO - Giordania 11
MA - Marocco 10
CL - Cile 9
AE - Emirati Arabi Uniti 8
LT - Lituania 8
MY - Malesia 8
TN - Tunisia 8
EU - Europa 7
KE - Kenya 7
PY - Paraguay 7
CZ - Repubblica Ceca 6
DK - Danimarca 6
HU - Ungheria 6
NZ - Nuova Zelanda 6
PH - Filippine 6
AM - Armenia 5
AZ - Azerbaigian 5
BY - Bielorussia 5
BA - Bosnia-Erzegovina 4
CR - Costa Rica 4
GA - Gabon 4
HN - Honduras 4
KZ - Kazakistan 4
MK - Macedonia 4
NP - Nepal 4
PA - Panama 4
PE - Perù 4
UY - Uruguay 4
ET - Etiopia 3
GT - Guatemala 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
NG - Nigeria 3
OM - Oman 3
PR - Porto Rico 3
SI - Slovenia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BF - Burkina Faso 2
BH - Bahrain 2
CG - Congo 2
LB - Libano 2
NI - Nicaragua 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
AL - Albania 1
AO - Angola 1
BG - Bulgaria 1
Totale 18.669
Salva come PNG Salva come JPEG
Città #
Singapore 937
Ashburn 745
Beijing 529
Chandler 523
San Jose 436
Fairfield 407
Munich 388
Houston 360
Santa Clara 319
Dublin 302
Mcallen 278
Montréal 273
Turin 269
Torino 201
Woodbridge 199
Ann Arbor 182
Seattle 181
Milan 178
New York 157
Wilmington 146
Helsinki 144
Jacksonville 138
Dallas 137
Ho Chi Minh City 127
Los Angeles 124
Nyköping 121
Cambridge 117
The Dalles 114
Shanghai 113
Columbus 106
Hong Kong 106
Pisa 101
Warsaw 98
Hanoi 95
Redwood City 94
Seoul 93
Lauterbourg 92
Medford 89
Hefei 84
Rome 81
Dearborn 79
Villeurbanne 78
Princeton 77
Guangzhou 74
Tokyo 64
Buffalo 62
Council Bluffs 57
Dong Ket 55
Jakarta 54
Boardman 53
Nanjing 51
São Paulo 49
Chicago 45
Montreal 44
Boston 41
Taipei 41
Fremont 40
Hangzhou 40
San Diego 38
Toronto 38
Turku 37
Phoenix 34
Frankfurt am Main 32
Washington 31
Atlanta 30
Nuremberg 30
Wuhan 30
Denver 26
Naples 26
Silver Spring 26
Bengaluru 25
Florence 25
Xian 24
London 23
Vienna 23
Zhengzhou 23
Mexico City 22
Brussels 21
Istanbul 21
Madrid 21
Orem 21
Brooklyn 19
Lappeenranta 19
Berlin 18
Dresden 18
Pune 18
Redondo Beach 18
San Francisco 18
Bologna 17
Johannesburg 17
Paris 17
Verona 17
Changsha 16
Chengdu 16
Genoa 16
Hebei 16
Palermo 16
Tianjin 16
Amsterdam 15
Belo Horizonte 15
Totale 11.137
Salva come PNG Salva come JPEG
Nome #
Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective. 1.443
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial 1.140
Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity? 637
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group 559
Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy 480
Cytokine Induced Killer cells kill chemo-surviving melanoma cancer stem cells 478
BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody 352
Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. 314
Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors. 306
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models 284
VEGF blockade enhances the antitumor effect of BRAFV600E inhibition 262
Post-Transplant Cyclophosphamide and Tacrolimus–Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors 260
Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. 249
Adoptive immunotherapy against ovarian cancer 248
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma 235
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy 232
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination 230
Pazopanib and trametinib as a synergistic strategy against osteosarcoma: Preclinical activity and molecular insights 229
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells 227
NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives 225
Abstract LB-366: Everolimus (EV) potentiates Sorafenib (SOR)activity in osteosarcoma (OS) preclinical models: a combination targeting the crosstalk between ERK1/2 and mTORC1/2 signaling pathways 224
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy 220
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer 219
CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes 215
Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors 214
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity 212
Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells. 205
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells 204
Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy 188
Activity of cytokine-induced killer cells against bone and soft tissue sarcoma. 187
Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer 184
Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives 184
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma 183
Recruitment, infiltration and cytotoxicity of hla-independent killer lymphocytes in three-dimensional melanoma models 175
Abstract 5603: Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies 175
Next generation immune-checkpoints for cancer therapy 171
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. 169
Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective 168
Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers. 162
Abstract 3998: Preclinical efficacy of a synthetic Notch-based combinatorial immunotherapy against colorectal cancer with HER2 amplification 159
Cytokine Induced Killer cells immunotherapy overcomes the resistance to MET tyrosine kinase inhibitors in nonsmall cell lung cancer 154
Treatment of metastatic melanoma: a multidisciplinary approach 152
Effective Activity of Cytokine Induced Killer Cells against Autologous Metastatic Melanoma including Cells with Stemness Features. 150
Epha2 expression in bone sarcomas: Bioinformatic analyses and preclinical characterization in patient-derived models of osteosarcoma, ewing’s sarcoma and chondrosarcoma 149
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours 149
Cytokine-induced killer cells as immunotherapy for solid tumors: current evidences and perspectives 148
Veliparib: a new therapeutic option in ovarian cancer? 148
Efficient transcriptional targeting of human hematopoietic stem cells and blood cell lineages by lentiviral vectors containing the regulatory element of the Wiskott-Aldrich Syndrome gene 147
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST 145
Adoptive immunotherapy against sarcomas. 145
Immunotherapy associated pulmonary toxicity: Biology behind clinical and radiological features 143
Cytokine profiling of end stage cancer patients treated with immunotherapy 142
Recent advances in the development of breast cancer vaccines. 141
Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells 140
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma 139
Dual VEGFA/BRAF targeting boosts PD-1 blockade in melanoma through GM-CSF-mediated infiltration of M1 macrophages 136
Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks. 136
Parp1 inhibitor and trabectedin combination does not increase tumor mutational burden in advanced sarcomas—a preclinical and translational study 134
Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis 134
Cytokine-Induced Killer (CIK) Cells from Colorectal Cancer Patients after Nonmyeloablative Hematopoietic Cell Transplantation: Tumor Killing Capacity and Alloreactivity across MHC Barriers 133
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification 132
Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour 132
INCIDENCE OF HHV-6 AFTER NONMYELOABLATIVE HSCT IN REFRACTORY MALIGNANCIES 127
Cytokine-induced killer cells engineered with exogenous t-cell receptors directed against melanoma antigens: Enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition 125
Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD 124
Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation 122
Comparison of post-transplant events and outcomes in patients affected by haematological or solid malignancies undergone to a non-myeloablative allogeneic haematopoietic stem cell transplantation in progressive disease 121
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers 120
The Combination of Sorafenib and Everolimus abrogates mTORC-1 and mTORC2 up-regulation in preclinical models of Osteosarcoma. 120
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study 118
Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19 117
Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors. 116
MET Oncogene Targeting for Cancer Immunotherapy 114
Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective 112
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies 109
Alloreactivity and antitumor activity segregate within two distinct subsets of Cytokine-Induced Killer Cells: Implications for their infusion Across major HLA-barriers. 105
Delving into PARP inhibition from bench to bedside and back 105
Predictive and dynamic signature for anti-angiogenics in combination with PD-1 inhibitor in soft-tissue sarcoma: correlative studies linked to the IMMUNOSARC trial 103
TCR gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naïve and memory T-cells without prior stimulation of endogenous TCR 98
Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. 95
Oncoretroviral and Lentiviral Transduction of Donor T Cells to Facilitate Engraftment of Dog Leukocyte Antigen (DLA)-Haploidentical T-Cell-Depleted Marrow 92
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review 91
Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade 90
The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes 90
Shifting Shapes: The Endothelial-to-Mesenchymal Transition as a Driver for Cancer Progression 90
Epigenetic determinants in soft tissue sarcomas: molecular mechanisms and therapeutic targets 90
Fibroblasts Impair Migration and Antitumor Activity of NK-92 Lymphocytes in a Melanoma-on-Chip Model 89
PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade 89
Sequential Lentiviral Transduction Conferring Simultaneous Sensitivity to Ganciclovir and Resistance to Mycophenolate Mofetil 86
Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy 75
Outcome of allogeneic hematopoietic cell transplantation (HCT) for patients with severe aplastic anemkia (SAA) above the age of 40 years 74
Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. 72
Cytokine induced killer cells as promising immunotherapy for solid tumors 70
Role of interferon in melanoma: old hopes and new perspectives 69
Treating breast cancer with cell-based approaches: an overview 66
Redirectedt cells in cancer therapy 65
Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect 61
Redirecting GVT after Allografting in Colorectal Cancer: Active Vaccination and Adoptive Immunotherapy 59
Development and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translation 58
Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study 58
Totale 18.922
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.290
article - articoli 0
book - libri 0
conference - conferenze 4.940
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.230
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.235 69 91 48 74 73 47 86 74 60 111 279 223
2022/20231.779 126 171 42 174 129 400 148 127 216 53 123 70
2023/20241.074 109 158 74 84 62 161 56 59 11 75 101 124
2024/20252.574 57 161 156 223 462 204 90 163 255 211 244 348
2025/20265.822 615 316 307 669 645 267 771 229 504 399 304 796
2026/2027170 170 0 0 0 0 0 0 0 0 0 0 0
Totale 19.120